#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study

Summit Therapeutics at #ASCO2026 (Karen Weintraub for Endpoints News) May 31, 2026 08:00 AM EDTUpdated 12:34 PM R&D Sum­mit, Ake­so drug re­duces death by 34% in Chi­na lung can­cer study. Here’s what it means Max Gelman Senior Editor CHICA­GO — The lead­ing drug in bio­phar­ma’s hottest im­munother­a­py race re­duced the risk of death by 34% in pre­vi­ous­ly un­treat­ed Chi­nese lung can­cer pa­tients, com­pared … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER